259
Participants
Start Date
October 3, 2017
Primary Completion Date
November 2, 2020
Study Completion Date
November 2, 2020
Evolocumab
Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
Placebo
Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
University of Florida, Jacksonville
Collaborators (1)
Amgen
INDUSTRY
University of Florida
OTHER